RT Book, Section A1 Holzen, Urs von A1 Mansour, John C. A1 Schwarz, Roderich E. A2 Morita, Shane Y. A2 Balch, Charles M. A2 Klimberg, V. Suzanne A2 Pawlik, Timothy M. A2 Posner, Mitchell C. A2 Tanabe, Kenneth K. SR Print(0) ID 1145761735 T1 Multimodality Therapy of Gastric Cancer: Western Experience T2 Textbook of Complex General Surgical Oncology YR 2018 FD 2018 PB McGraw-Hill Education PP New York, NY SN 9780071793315 LK accesssurgery.mhmedical.com/content.aspx?aid=1145761735 RD 2024/10/08 AB Gastric cancer remains one of the most common malignancies and a high cause of mortality worldwide. In the United States and the Western world, the incidence of gastric cancer has been declining over the last decades. Moreover, a shift in location occurred in the last 20 years with a decline of tumors of the gastric body and antrum and an increase in tumors of the proximal stomach. In particular, the incidence of adenocarcinoma of the esophagogastric junction (EGJ) is increasing steadily and is among the fastest growing tumors in the United States. Despite recent advances in surgical technique and multimodality treatment, gastric carcinoma still has a high mortality. Unfortunately, at time of diagnosis about 50% of patients already present with systemic disease and are not amenable to surgical resection. Survival after resection historically resulted in very poor results. These poor results led to efforts to improve the outcome of these patients with the addition of systemic adjuvant or neoadjuvant therapy.